Predictive factors for refractory stage I and II anti-resorptive agent-related osteonecrosis of the jaw

Takahiro Shimizu¹ · Mai Kim¹,² · Trang Thuy Dam² · Jun Kurihara¹ · Masaru Ogawa¹ · Takaya Makiguchi¹ · Satoshi Yokoo¹

Received: 28 January 2021 / Accepted: 21 June 2021 / Published online: 3 July 2021
© The Author(s) 2021

Abstract

Objectives We aimed to predict the possibility of patients with stage I and II anti-resorptive agent-related osteonecrosis of the jaw (ARONJ) developing resistance to our treatment protocol by evaluating their clinical and imaging factors.

Materials and methods We enrolled 58 patients with ARONJ who underwent imaging modality. As objective variables, we considered the healing, stage-down, and stable stages as successful outcomes, and the stage-up stage as resistant-to-treatment. As explanatory variables, we investigated the clinical and imaging factors. Furthermore, we examined stage-down as an improvement outcome to compare with the stable and stage-up stages, which were considered as no-improvement outcomes. We conducted unpaired between-group comparisons on all explanatory variables using \( \chi^2 \) tests for independence.

Results Among 58 patients, the treatment was successful in 53 (91.4%); however, the disease was resistant in five (8.6%). Among the clinical factors, the resistant patients had a longer duration of administration of bone-modifying agents (BMAs) (cut-off: 1251 days, \( p = 0.032 \), odds ratio = 11.2, 95% confidence interval 1.115–122.518). In addition, the target disease that was being treated bone metastasis of malignant tumor was the only significant refractory factor (\( p = 0.024 \), OR: 3.667 95% CI 1.159–11.603)

Conclusions A combination of metabolic and morphological imaging modalities may be useful for oral surgeons to evaluate the disease activity and predict course of refractory ARONJ.

Keywords ARONJ · BMA administration period · One scintigraphy · PET · CT · Refractory factor

Introduction

Several imaging modalities and analytical methods have been used to assess the course of anti-resorptive agent-related osteonecrosis of the jaw (ARONJ) and determine its clinical stages [1]. According to the Japanese Society for Oral and Maxillofacial Radiology [2], 64% of oral radiologists believe that dental panoramic radiography (DPR) is the best screening modality for bisphosphonate-related osteonecrosis of the jaw (BRONJ), while 68% of oral radiologists prefer intraoral radiography, as it enables clear visualization of the trabecular bone structure around the tooth and the surrounding alveolar processes. Intra-oral radiography and DPR can be used to diagnose ARONJ in the oral or maxillofacial regions of asymptomatic patients treated with low-dose bone-modifying agents (BMAs) [2]. Computed tomography (CT) and dental cone-beam CT are effective in patients with suspected ONJ, as they can detect early changes in the trabecular and cortical bones [2]. Furthermore, 2-(18F)-fluoro-2-deoxy-D-glucose position emission tomography (FDG-PET) is one of the most effective techniques to detect and evaluate the severity of ARONJ [3]. In a systematic review on the development of BRONJ, Khan et al. [4] identified infection, administration of BP, tooth extraction, and underlying anemia as risk factors. A 2017 position paper by the Japanese Allied Committee on Osteonecrosis of the Jaw stated that surgical stresses, such as extraction, dental implant surgery, and periodontal surgery, were considered as local risk factors, while steroid
treatment, diabetes, malignant tumors, cancer chemotherapy, smoking, and poor oral hygiene were considered as systemic risk factors [5].

To date, studies on the imaging modalities and risk factors of ONJ have focused on assessing its stage and predicting its development, and factors associated with refractory disease or an exacerbation of ONJ have not been investigated in detail. The only predictive data on surgical outcomes are those reported by Fleisher et al. [6, 7] using FDG-PET. It is important to understand these factors in detail to treat ARONJ successfully.

This study aimed to predict the possibility of treatment resistance among ARONJ patients based on clinical and imaging factors.

Patients and methods

This study was approved by the institutional review board of our hospital (No. IRB 2018–149).

Treatment protocol for stage I and II ARONJ

The treatment protocol for stages I and II ARONJ at our institution is described in Fig. 1 [8]. We included 58 patients with ARONJ who underwent treatment under this protocol over 9 years (January 2009 to December 2017) (Table 1). The main purpose of this protocol was to prevent the progression of osteonecrosis into osteomyelitis and preserve the patients’ quality of life. The approach was divided into conservative treatment and radical surgery. Conservative treatment included administration of oral or intravenous antibacterial drugs, antimicrobial mouthwash, local irrigation, oral hygiene management by educating the patient, and sequestrectomy or curettage of the necrotic bone. Sequestration formation involves pathological encapsulation during the wound healing process, and it is a healing mechanism induced by a normal foreign body reaction in the bone; accordingly, sequestrectomy is classified as a conservative treatment [9]. Conservative treatment was performed for a maximum of approximately 12 months. Radical surgery was of two types: (1) marginal shave/resection, wherein the surrounding bone, including the necrotic part, was extensively resected until the fresh bone was exposed macroscopically; and (2) segmental resection, wherein the necrotic part was resected with a safe region including the healthy bone. There were four possible treatment outcomes: (1) Healing occurred when objective and subjective symptoms (such as bone exposure and infection) disappeared after the therapeutic intervention and the bone was covered by the epithelium; (2) Stage-down corresponded to the observation of objective and subjective findings that were reduced or down-staged; (3) No improvement corresponded to the maintenance of objective and subjective findings; and (4) Progression corresponded to the appearance of objective and subjective findings.
(3) Stable denoted no change in the disease stage or clinical findings after the treatment; and (4) Stage-up indicated the progression of the disease to an advanced stage.

In this protocol, previously reported risk factors, such as steroid treatment, diabetes, malignant tumors, cancer chemotherapy, and smoking were not assessed [5]. Moreover, drug withdrawal was also not assessed because of the seriousness of the causative disease, such as osteoporosis and bone metastasis of malignancy [10–15].

**Clinical factors**

We evaluated clinical factors, such as age, sex, staging at the time of the first examination, the region of disease development (maxilla or mandible, and anterior/premolar or molar), administered drugs and their administration periods, the target disease that was being treated (i.e., osteoporosis or bone metastasis of the malignant tumor), and risk factors (i.e., steroids treatment, diabetes, malignant tumors, cancer chemotherapy, and smoking). The stage of ARONJ was diagnosed based on a novel diagnostic definition for ARONJ, as proposed by the Japanese Allied Committee (in the position paper published in 2017) [5] and the American Association of Oral and Maxillofacial Surgeons [16]. Regarding administration of BMAs, specific routes of administration are considered important, such as injection for bone metastasis of malignant tumors, and oral drugs for osteoporosis. Denosumab is an injection that it is used at a low dose to treat osteoporosis, and at a high dose to treat bone metastasis of malignant tumors; the treatment of the target disease is the same as the dosage classification of the drug (high and low dose).

**Imaging factors**

During the first examination, we performed DPR for all 58 patients, and performed CT in 57 patients, bone scintigraphy in 23 patients, and FDG-PET/CT to observe the course of the primary malignant lesion in 15 patients. The DPR and CT images were evaluated as per Obinata et al.’s method [17]. Using these images, we classified osteolysis and osteonecrosis (designated as Score 1) into the following grades: Grade 0 = none; Grade 1 = localized in the alveolar process of the jaw; and Grade 2 = extending beyond the mandibular canal or maxillary sinus. Sequestration, periosteal reaction, and pathological fractures (Score 2) were classified as follows: Grade 0 = not observed; and Grade 1 = observed. CT images that showed disease spread in the soft tissues (Score 3) were additionally classified as follows: Grade 0 = not observed; Grade 1 = localized around the alveolar bone; and Grade 2 = extending into the masticatory muscle, masticatory space, subcutaneous adipose tissue, or maxillary sinus (Fig. 2A; Table 2). The bone scintigraphy (BS) score was defined as follows: Grade 0 = absent; Grade 1 = spot; and Grade 2 = spread (Fig. 2B; Table 2). ARONJ-induced changes in regions showing changes in bone metabolism were based on the PET/CT uptake score as follows: Grade 0 = absent; Grade 1 = spot; and Grade 2 = spread (Fig. 2C; Table 2). We also calculated the maximum standardized uptake value (SUV$_\text{max}$). The aforementioned grades were
First, we performed a power analysis to assess the appropriateness of the sample size by G*Power software (Universität Düsseldorf, Düsseldorf, Germany).

Next, concerning the objective variables, we defined the healing, stage-down, and stable stages as successful outcomes, and the stage-up stage as resistant. To obtain explanatory variables, we determined the cut-off values for the continuous variables of age (68 years), drug administration period (1251 days), and SUVmax (6.92) using receiver operating characteristic curves and converted them to binary variables. A DPR score of 1, CT scores of 3, and the BS and PET scores were converted to binary variables of Grade 0, 1 vs. Grade 2, Grade 0 and 1.
vs. Grade 2, and absent and spot vs. spread, respectively. Unpaired between-group comparisons were performed for all explanatory variables using the $\chi^2$ test for independence. For significantly different explanatory variables, the odds ratio (OR) was calculated. Furthermore, we examined stage-down as an improvement outcome to compare with the stable and stage-up stages, which were considered as no-improvement outcomes, using the $\chi^2$ test for independence.

Statistical analyses were performed using SPSS software for Windows (version 25; IBM Corp., Armonk, NY). A $p$ value < 0.05 was considered significant.

### Results

#### Patient background

The patients’ background characteristics are presented in Table 1. The patients’ age ranged from 23–93 years, with a median age of 68 years. There were 22 male (37.9%) and 36 female participants (62.1%). ARONJ developed in the maxilla, mandible, anterior and premolar tooth region, and molar region in 21 (33.9%), 37 (66.1%), four (6.9%), and 57 (93.1%) cases, respectively. The stage at the time of the first examination was I and II in 19 and 39 cases, respectively. The target disease was bone metastasis of malignant tumor in 37 cases and osteoporosis in 21. The drug was intravenously administered to all 37 patients with malignancy and in five out of 21 patients with osteoporosis.

#### Treatment outcome

The treatment was successful in 53 (91.4%) of the 58 patients, but the disease was resistant in five patients (8.6%). The period of observation was 1 year after the start of the treatment.

#### Analysis of factors associated with the refractory cases

At first analysis, regarding the objective variables, we defined the healing, stage-down, and stable stages as successful outcomes, and the stage-up stage as resistant-to-treatment. Considering the clinical factors, the refractory cases had a significantly higher BMA administration period (cut-off: 1251 days; $p = 0.032$; OR: 11.2; 95% confidence interval [CI] 1.115–122.518), and a tendency for high-dose drug administration for bone metastasis of malignant tumors ($p = 0.102$). No significant differences were observed for

### Imaging analysis

CT was performed using a SOMATOM Definition Flash (Siemens Healthcare Co. Ltd., Forchheim, Germany) and a Light Speed VCT (GE Healthcare Co. Ltd., Chicago, IL, USA). For BS, a low-energy and high-resolution E. CAM scintigraphy apparatus (Canon Co., Ltd., Tochigi, Japan) was used, with technetium-99m hydroxymethylene diphosphonate ($^{99m}$Tc-HMDP; Nihon Medi-Physics Co., Ltd., Tokyo, Japan) and technetium-99m methylene diphosphonate ($^{99m}$Tc-MDP; Fujifilm Toyama Chemical Co. Ltd., Tokyo, Japan) injected at 740 MBq in each patient. The matrix size was set at 256 × 25 pixels, and the uptake time was 240 s × 2. For PET, 4 Mbq/kg of FDG was intravenously administered after the patients had fasted for at least 6 h. After 60 min, PET images were acquired in a 700-mm visual field using a scanner with 3.27-mm slice thickness (Discovery STE, GE Healthcare). Three-dimensional data were collected at 3 min/bed position, followed by image reconstruction using the 3D-OSEM method. Segmented attenuation correction was applied using X-ray CT (140 kV, 120–240 mAs) and 128×128 matrix images were prepared.

### Table 2 Criteria of imaging diagnosis (grading)

| DPR/CT score | Grade | Description |
|--------------|-------|-------------|
| Score 1 Osteolysis and osteosclerosis (DPR/CT) | 0 | Not observed |
| 1 | Located in alveolar bone |
| 2 | Extended into mandibular canal/ maxillary sinus |
| Score 2 Sequester, periosteal reaction and pathological fracture (DPR/CT) | 0 | Absent |
| 1 | Present |
| Score 3 Spread into soft tissue (CT) | 0 | Not observed |
| 1 | Spread into alveolar |
| 2 | Spread into masticator muscles or subcutaneous adipose tissue or maxillary sinus |
| Bone scintigraphy(BS) score, FDG-PET/CT(FDG) score | 0 | Absent |
| 1 | Spot |
| 2 | Spread |
Table 3 Clinical and imaging factors related to treatment outcomes compared healing, stage-down, and stable stages as successful the stage-up stage as resistant (Results of univariable analysis with ×2 test for independence)

| Clinical factors | Successful (n=57) | Resistant (n=5) | p value | Odds ratio | 95% CI  |
|------------------|-------------------|-----------------|---------|------------|---------|
| Age              |                   |                 |         |            |         |
| <68y             | 24                | 1               | 0.275   |            |         |
| ≥68y             | 29                | 4               |         |            |         |
| Administration period | (n=38)   | (n=5) |         |            |         |
| <1251 days       | 28                | 1               |         |            |         |
| ≥1251 days       | 10                | 4               | 0.032*  | 11.2       | 1.115–112.518 |
| Gender           |                   |                 |         |            |         |
| Male             | 20                | 2               | 0.635   |            |         |
| Female           | 33                | 3               |         |            |         |
| Stage at the primary consultation |       |                 |         |            |         |
| I                | 18                | 1               |         |            |         |
| II               | 35                | 4               | 0.467   |            |         |
| Location         |                   |                 |         |            |         |
| Maxilla          | 20                | 1               |         |            |         |
| Mandibular       | 33                | 4               | 0.398   |            |         |
| Anterior and premolar |      |                 |         |            |         |
| Molar            | 49                | 5               | 0.69    |            |         |
| Medication target diseases |         |                 |         |            |         |
| Bone metastasis of malignant tumor | 32 | 5 |         |            |         |
| Osteoporosis     | 21                | 0               | 0.095   |            |         |
| Administration route |       |                 |         |            |         |
| Intravenous      | 38                | 5               |         |            |         |
| Oral             | 15                | 0               | 0.21    |            |         |
| Risk factor      |                   |                 |         |            |         |
| Present          | 44                | 5               | 0.416   |            |         |
| Absent           | 9                 | 0               |         |            |         |
| Imaging factors  |                   |                 |         |            |         |
| DPR              | (n=53)            | (n=5)           |         |            |         |
| Score 1          |                   |                 |         |            |         |
| Grade 0,1        | 25                | 1               |         |            |         |
| Grade 2          | 28                | 4               | 0.248   |            |         |
| Score 2          |                   |                 |         |            |         |
| Grade 0          | 46                | 3               |         |            |         |
| Grade 1          | 7                 | 2               | 0.168   |            |         |
| CT               | (n=48)            | (n=5)           |         |            |         |
| Score 1          |                   |                 |         |            |         |
| Grade 0,1        | 15                | 2               |         |            |         |
| Grade 2          | 33                | 3               | 0.52    |            |         |
| Score 2          |                   |                 |         |            |         |
| Grade 0          | 32                | 2               |         |            |         |
| Grade 1          | 16                | 3               | 0.239   |            |         |
| Score 3          |                   |                 |         |            |         |
| Grade 0,1        | 36                | 4               |         |            |         |
| Grade 2          | 12                | 1               | 0.643   |            |         |
| Bone scintigraphy | (n=28)             | (n=5)           |         |            |         |
| Grade 0,1        | 16                | 1               |         |            |         |
| Grade 2          | 12                | 4               | 0.149   |            |         |
| FDG-PET/CT       | (n=12)            | (n=3)           |         |            |         |
| Grade 0,1        | 11                | 2               |         |            |         |
| Grade 2          | 1                 | 1               | 0.371   |            |         |
imaging factors; however, refractory cases tended to exhibit a spreading pattern (BS score: Grade 2; \( p = 0.133 \)) (Table 3). At second analysis, we used the stage-down stage as an improvement outcome to compare with the stable and stage-up stages as no-improvement outcomes. The target disease that was being treated (osteoporosis or bone metastasis of malignant tumor) was the only significant refractory factor \( (p = 0.024, \text{OR: } 3.667 \text{ 95\% CI 1.159–11.603}) \), and there were no significant differences among all imaging factors (Table 4).

**Common factors in the five refractory cases**

We investigated the common factors in the five refractory cases. Among the clinical factors, high-dose drug administration for bone metastasis of malignant tumor was common to all cases, and the disease was located in the mandibular molar region in four out of five cases (Table 5). Two imaging factors, DPR/CT score 1 (osteolysis and osteonecrosis: Grade 2, extension into the mandibular canal/maxillary sinus) and BS score 2 (spread pattern) were common in four out of five cases. An \( \text{SUV}_{\text{max}} \) value of 8.75 was considered to be high in one case, although the PET score of the patient was of Grade 1 (Case 5) (Table 6; Fig. 3).

**Discussion**

Our treatment protocol for stages I and II ARONJ was based on the mechanism and pathophysiology of ARONJ development. In a previous study [8], no background risk factors that influenced the healing of stages I and II ARONJ were identified. Thus, we did not consider risk factors while administering our protocol. In this study, we found that the risk factors were not similar to refractory factors. A BMA administration period of > 3.5 years (1251 days) was the only predictor of treatment resistance. In addition, we did not investigate drug withdrawal during treatment because of the seriousness of the causative diseases. Therefore, the treatment outcome was favorable in 91.4% of stage I and II ARONJ patients, which suggested that the majority of them can be healed and stabilized by infection control and patient education.

Recognizing the differences between osteonecrosis and osteomyelitis is important when considering the mechanism of ARONJ development. Osteonecrosis can be an ischemic and aseptic process that frequently develops in the femoral head and causes localized bone necrosis by blocking its blood supply. This condition transitions into osteomyelitis when a bacterial infection occurs in the necrotic bone; this similarly occurs in the maxillary and mandibular bones. With this background, we hypothesized that the fundamental pathophysiology of ARONJ development is the loss of balance in local bone remodeling due to osteoporosis or bone metastasis of the malignant tumor. Excess suppression of osteoclastic activity due to the long-term use of BMAs inhibits bone resorption, which in turn inhibits bone metabolism and leads to a state of low bone turnover. This condition progresses into metabolic disturbance due to reduced formation of the medullary cavities, which distributed, such as osteosclerosis, in morphological image.

The decreasing blood circulation volume subsequently causes necrosis of the jaw. Prolonged circulatory failure reduces local immunity and makes the necrotic bone susceptible to infections from oral bacteria, which results in osteomyelitis of the jaw. Therefore, we believe that osteomyelitis occurs in a state of metabolic suppression and circulatory failure, where the normal mechanism of wound healing is not triggered, leading to a refractory condition. In a study on the developmental mechanism of BRONJ using diagnostic imaging, Obayashi et al. [18] observed that the increased levels of \( ^{99m} \text{Tc-MDP} \) in the bone were mainly a result of a low local pH, which induced acidosis and increased accumulation of BMAs. Metabolic disturbance was associated with prolonged hypoxic state of the bone and inhibition of the normal mechanism of wound healing, which eventually led to refractory conditions.

In this study, five patients (8.6%) were resistant to our ARONJ treatment protocol. Thus, we examined the possibility of predicting refractory stage I and II ARONJ using the clinical and imaging factors. First, the healing, stage-down, and stable stages were considered as successful outcomes to compare with the stage-up stage, which was considered as resistant-to-treatment. Next, we examined stage-down as an improvement outcome to compare with the stable and stage-up stages, which were considered as no-improvement outcomes. A BMA administration period of 3.5 years was an important predictor of treatment resistance. High-dose treatment of bone metastasis of malignant tumors was common to all patients, and the lesion was located in the mandibular molar region in four out of five patients. Two imaging factors, DPR/CT score 1 and BS score of Grade 2 (spread pattern), were also found in four patients. Based on
| Clinical factors | Improvement (n = 30) | No-improvement (n = 28) | p value | Odds ratio | 95% CI |
|------------------|----------------------|-------------------------|---------|------------|--------|
| **Age**          |                      |                         |         |            |        |
| < 68y            | 12                   | 13                      |         |            |        |
| ≥ 68y            | 18                   | 15                      | 0.621   |            |        |
| **Administration period** |                |                         |         |            |        |
| < 1251 days      | 14                   | 16                      |         |            |        |
| ≥ 1251 days      | 11                   | 11                      | 0.812   |            |        |
| **Gender**       |                      |                         |         |            |        |
| Male             | 11                   | 11                      |         |            |        |
| Female           | 19                   | 17                      | 0.837   |            |        |
| **Location**     |                      |                         |         |            |        |
| Maxilla          | 11                   | 10                      |         |            |        |
| Mandibular       | 19                   | 18                      | 0.940   |            |        |
| Anterior and premolar |                |                         |         |            |        |
| Molar            | 28                   | 26                      | 0.667   |            |        |
| **Medication target diseases** |            |                         |         |            |        |
| Bone metastasis of malignant tumor | 15 | 22 |         |            |        |
| Osteoporosis     | 15                   | 6                       | 0.024*  | 3.667      | 1.159–11.603 |
| **Administration route** |                |                         |         |            |        |
| Intravenous      | 19                   | 24                      |         |            |        |
| Oral             | 11                   | 4                       | 0.520   |            |        |
| **Risk factor**  |                      |                         |         |            |        |
| Present          | 23                   | 26                      |         |            |        |
| Absent           | 7                    | 2                       | 0.089   |            |        |
| **Imaging factors** |                |                         |         |            |        |
| DPR              | (n = 30)             | (n = 28)                |         |            |        |
| Score 1          |                      |                         |         |            |        |
| Grade 0.1        | 14                   | 12                      |         |            |        |
| Grade 2          | 16                   | 16                      | 0.771   |            |        |
| Score 2          |                      |                         |         |            |        |
| Grade 0          | 26                   | 23                      |         |            |        |
| Grade 1          | 4                    | 5                       | 0.454   |            |        |
| CT               | (n = 27)             | (n = 26)                |         |            |        |
| Score 1          |                      |                         |         |            |        |
| Grade 0.1        | 9                    | 8                       |         |            |        |
| Grade 2          | 18                   | 18                      | 0.842   |            |        |
| Score 2          |                      |                         |         |            |        |
| Grade 0          | 18                   | 16                      |         |            |        |
| Grade 1          | 9                    | 10                      | 0.697   |            |        |
| Score 3          |                      |                         |         |            |        |
| Grade 0.1        | 21                   | 19                      |         |            |        |
| Grade 2          | 6                    | 7                       | 0.691   |            |        |
| Bone scintigraphy |                      |                         |         |            |        |
| Grade 0.1        | 11                   | 6                       |         |            |        |
| Grade 2          | 7                    | 9                       | 0.227   |            |        |
| FDG-PET/CT       | (n = 6)              | (n = 9)                 |         |            |        |
| Grade 0.1        | 6                    | 7                       | 0.371   |            |        |
| Grade 2          | 0                    | 2                       |         |            |        |
| $S_{\text{UV}}^\text{max}$ |                |                         |         |            |        |
these findings, we postulated that a patient having a BMA administration period of > 3.5 years, disease development in the mandibular molar region, a target disease that was being treated as bone metastasis of a malignant tumor, morphologically extensive osteosclerotic features, and metabolic abnormalities may develop refractory ARONJ.

Regarding the diagnostic imaging of ARONJ, Fleisher et al. [6, 7] showed that FDG-PET/CT can be used to visualize a limited region with elevated metabolism as it can depict metabolic and morphological changes. Thus, regions with ARONJ-induced metabolic changes that are not detectable on plain radiography can be identified using this method. Therefore, they demonstrated that FDG-PET-CT may also help predict the course of postsurgical healing, as a limited FDG uptake in the alveolus, torus, and/or basal bone superior to the mandibular canal is a predictor of successful healing after marginal resection (positive predictive value = 1.0) [6, 7]. FDG accumulates in the inflammatory cells in the sequestrum or bone marrow on FDG-PET, and this increased blood flow activity is evaluated with 99mTc on BS; this mechanism led Kitagawa et al. [19] to suggest that 99mTc accumulation may indicate an inflammatory reaction. This accumulation mechanism is undoubtedly useful for evaluating the activity and treatment effects of ARONJ [20]. In the five refractory cases examined in this study, the morphological DPR and CT scores were of Grades 0–2 and 0–1, respectively, but a bone metabolic factor, the BS score, was of Grade 2 (spread) and was accompanied by a high SUVmax value of 8.75. Thus, evaluating the activity of refractory ARONJ may be difficult by conventional imaging, and it is important to further analyze the metabolic changes using FDG-PET/CT and BS. Cases 2 and 5, which showed a spread pattern on BS also exhibited a spot pattern on FDG-PET/CT. As a difference in the pathology of regions with a metabolic abnormality can be investigated by combining images showing different rates of drug accumulation, it may be possible to use this relationship to predict treatment resistance.

This study had a few limitations that should be acknowledged. First, we performed FDG-PET/CT to detect the
metastasis and progression of the primary malignant disease rather than to examine ARONJ. Thus, there was a significant time lag between the timepoints of acquisition of data and the exacerbation of clinical symptoms of ARONJ. Future studies should be performed in a medical care environment, where FDG-PET/CT would be conducted to plan ARONJ treatments. Second, BS was useful for identifying the inflammatory region; however, identifying the inflammatory activity was difficult as there was no objective index to evaluate the accumulated intensity or volume of the inflammation. To solve this issue, we recommend that SPECT/CT be used more frequently to quantitatively analyze the BS score and improve the methods of mapping bone metabolism.
Fig. 3 Imaging features in five refractory cases. Patient 1. Location: left molar in the maxilla. a DPR: osteosclerotic changes extending to the maxillary sinus (black arrow); DPR score 1: Grade 2. b CT findings: osteosclerotic changes extending to the maxillary sinus (black arrow); CT score 1: Grade 2. Bone scintigraphy findings: spot accumulation pattern (black arrow). c BS score: Grade 1. Patient 2. Location: left molar region in the mandible. a DPR: osteosclerotic changes extending into the mandibular canal (black arrow). DPR score 1: Grade 2. b CT findings: osteosclerotic changes extending into the mandibular canal and causing a periosteal reaction (black arrow). CT score 1: Grade 2; CT score 2: Grade 1. e Bone scintigraphy findings: spread pattern (black arrow). BS score: Grade 2. FDG-PET/CT: spot pattern. d PET score: Grade 1. SUVmax: 4.41. Patient 3. Location: right molar region in the mandible. a DPR: osteosclerotic changes extending into the mandibular canal (black arrow). DPR score 1: Grade 2. b CT: spread of jaw inflammation to the masticatory muscles (black arrow). CT score 3: Grade 2. e Bone scintigraphy: spread pattern (black arrow). BS score: Grade 2. d FDG-PET/CT: spread pattern. PET score: Grade 2. SUVmax: 6.92. Patient 4. Location: right molar region in the mandible. a DPR: osteosclerotic changes extending into the mandibular canal and causing a periosteal reaction (white arrow). CT score 1: Grade 2; CT score 2: Grade 1. e Bone scintigraphy findings: spread pattern. BS score: Grade 2. Patient 5. Location: left premolar region in the mandible. a DPR: osteosclerotic changes in the alveolar bone (black arrow). DPR score 1: Grade 1. b CT findings: osteosclerotic changes in the alveolar bone (white arrow). CT score 1: Grade 1. e Bone scintigraphy findings: spread pattern. BS score: Grade 2. d FDG-PET/CT: spot pattern. PET score: Grade 1. SUVmax: 8.75. BS bone scintigraphy, DPR dental panoramic radiography, CT computed tomography, FDG 2-(18F)-fluoro-2-deoxy-D-glucose, PET position emission tomography, $SUV_{max}$ maximum standardized uptake value

Conclusion

Our treatment protocol successfully controlled ARONJ in 91.4% of our patients, suggesting that a majority of patients with stage I and II ARONJ can be healed and stabilized by infection control and patient education. Based on this study’s findings, we recommend that the risk of refractory ARONJ should be evaluated in patients who receive BMAs for > 3.5 years, those with lesions in the mandibular molar region, those in whom the target disease is treated as bone metastasis of the malignant tumor, and in those with morphological osteosclerotic findings and bone metabolic abnormalities. We believe that a combination of metabolic imaging modalities, FDG-PET/CT, and BS may be useful for oral surgeons and oral radiologists to evaluate the disease activity and predict the onset and course of refractory ARONJ in the future.

Acknowledgements We would like to thank Editage (www.editage.com) for English language editing.

Funding This study did not receive financial support from any funding organization.

Declarations

Conflict of interest The authors declare that they have no competing interests.

Ethical approval This study was approved by the institutional review board of Gunma University Hospital (No. IRB 2018–149).

Informed consent Written informed consent was obtained from all patients for the publication of this study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Berg BI, Mueller AA, Augello M, Berg S, Jaquieri C. Imaging in patients with bisphosphonate-associated osteonecrosis of the jaws (MRONJ). Dent J (Basel). 2016;4:29.
2. Taguchi A, Akiyama H, Koseki T, Shimizutani K. Recognition of bisphosphonate-related osteonecrosis of the jaw among oral and maxillofacial radiologists: results from a questionnaire-based survey in Japan. Oral Radiol. 2013;29:98–104.
3. Wilde F, Steinhoff K, Frerich B, Schulz T, Winter K, Hemprich A, et al. Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:412–9.
4. Khan A, Morrison A, Ruggiero S, Tetrads S, Davison KS, Peters E, et al. Response to comments on “diagnosis and management of osteoporosis of the jaw: a systematic review and international consensus.” J Bone Miner Res. 2015;30:1116–7.
5. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese allied committee on osteonecrosis of the jaw. J Bone Miner Metab. 2017;35:6–19.
6. Fleisher KE, Pham S, Raad RA, Friedman KP, Ghesani M, Chan KC, et al. Does fluorodeoxyglucose positron emission tomography with computed tomography treatment of medication-related osteonecrosis of the jaw? J Oral Maxillofac Surg. 2016;74:945–58.
7. Fleisher KE, Raad RA, Rakheja R, Gupta V, Chan KC, Friedman KP, et al. Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw. J Oral Maxillofac Surg. 2014;72:1957–65.
8. Kurihara J, Shimizu T, Sakaino S, Yokoo S (2017) The factors influencing the healing in stage I.; II cases of Anti-resorptive
agents-Related Osteonecrosis of the Jaw (ARONJ) induced by oral bisphosphonate preparation. Oral Sci Jpn 1–4
9. McHugh JB. Mandible and Maxilla. In: Goldblum JR, McKenny JK, Lamps LW, Myers JL, editors. Rosai and Ackerman’s Surgical Pathology. Philadelphia: Elsevier; 2011. p. 213.
10. Blauc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301:153–21.
11. McLeod K, Brodie MP, Fahey PP, Gray RA. Long-term survival of surgically treated hip fracture in an Australian Regional Hospital. Anaesthesiol Intensive Care. 2005;33:749–55.
12. Kanis JA. The incidence of hip fracture in Europe. Osteoporos Int. 1993;3:10–5.
13. Cummings SR, Ferrari S, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension. J Bone Miner Res. 2018;33:190–8.
14. Hagino H, Sakamoto K, Harada A, Nakamura T, Mutoh Y, Mori S, et al. Nationwide one-decade survey of hip fractures in Japan. J Orthop Sci. 2010;15:737–45.
15. Brumsch C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PH, Hamdy NA, Landman JO, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res. 2002;17:1057–64.
16. Salvatore LR, Thomas BD, John F, Reginald G, Tara A, Bhoomi M, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014;72:1938–56.
17. Obinata K, Shirai S, Ito H, Nakamura M, Carrozso M, Macleod I, et al. Image findings of bisphosphonate related osteonecrosis of jaws comparing with osteoradionecrosis. Dento Maxillo Fac Radiol. 2017;46:20160281.
18. Ohbayashi Y, Nakai F, Iwasaki A, Ogawa T, Yamamoto Y, Nishiyama Y, et al. The utility of bone scintigraphy in the assessment of mandibular metabolism during long-term bisphosphonate administration. Odontology. 2017;105:382–90.
19. Kitagawa Y, Ohga N, Asaka T, Sato J, Hata H, Helman J, et al. Imaging modalities for drug-related osteonecrosis of the jaw (3). Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw. Jpn Dent Sci Rev. 2019;55:65–70.
20. Watanabe S, Nakajima K, Mizokami A, Yaegashi H, Naguchi N, Kawashiri S, et al. Bone scan index of the jaw: a new approach for evaluating early-stage anti-resorptive agents-related osteonecrosis. Ann Nucl Med. 2017;31:201–10.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.